Iguratimod as an Alternative Therapy for Resistant Lupus Nephritis
April 1, 2020 An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants. Results were reported in Arthritis Research & Therapy. The small study included 14 patients with refractory lupus nephritis. Each were […]
Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis
May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […]
Study Finds Mycophenolate Mofetil Comparable to Standard Treatment for Pediatric Lupus Nephritis
March 19, 2019 A new study published in Lupus showed that mycophenolate mofetil (MMF) is comparable in effectiveness to the standard treatment intravenous cyclophosphamide (IVCYC) for lupus nephritis in pediatric patients. The study compared response to treatment, kidney damage, time needed to result in inactive lupus nephritis and disease flares. Of the 51 patients studied, […]
Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid
November 8, 2019 Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact the levels of mychophenolate acid (MPA), the main ingredient in the common standard treatment mycophenolate mofetil (CellCept®) for lupus nephritis. The drug-drug interaction (DDI) study was requested by the Food and Drug Administration to measure […]
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY. A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […]
LRA-Supported Researchers Developed a Model to Predict Full-Blown Lupus Nephritis Down the Road
A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed a set of standardized measures that promise to improve the way clinical trials in lupus nephritis (LN) are structured and how clinical researchers report their results. The findings will also help researchers in their search for […]
Good News from Aurinia Pharmaceuticals for Lupus Nephritis
September 25, 2018 Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of schedule. The company reported in a press release issued today that due to high patient demand, the target number of patients was surpassed with 358 lupus nephritis (LN) patients enrolled in sites across 27 countries. […]
Patients with Lupus Nephritis-Related Kidney Disease Are Living Longer
March 28, 2019 A new study published this March in Arthritis & Rheumatology found that deaths among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) fell significantly — by 32% —over the past two decades. The study took into account deaths from all causes, including deaths from cardiovascular disease (CVD) and infection. […]
Aurinia Moves Voclosporin Closer to FDA Approval for Lupus Nephritis
March 16, 2020 The Lupus Research Alliance is pleased to share an announcement from Aurinia Pharmaceuticals that moves its potential treatment for lupus nephritis, voclosporin, one step closer to approval by the U.S. Food and Drug Administration (FDA). The Company announced in a press release March 16 that it has started a Rolling Submission of […]
Better Survival Rates from Severe Lupus Nephritis
September 20, 2018 Significantly more people are surviving end-stage renal (kidney) disease caused by lupus nephritis according to a long-term analysis published in Arthritis & Rheumatology. The analysis of the national registry of 20,974 patients with end-stage renal disease (ESRD) during the years 1995 through 2014 found that mortality rates significantly declined. In addition, among […]